Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer

World Journal of Gastroenterology

Volumn 17, Issue 16, 2011, Pages 2109-2112

  Kemik, Ozgur ^a   Kemik, Ahu Sarbay ^b   Sümer, Aziz ^a   Dulger, Ahmet Cumhur ^a   Adas, Mine ^c   Begenik, Huseyin ^a   Hasirci, Ismail ^a   Yilmaz, Ozkan ^a   Purisa, Sevim ^b   Kisli, Erol ^a   Tuzun, Sefa ^d   Kotan, Cetin ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^d HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Gastric cancer; Matrix metalloproteinase 1; Tissue matrix metalloproteinase 1

Indexed keywords

INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; SEX DIFFERENCE; STOMACH CANCER; TUMOR VOLUME;

EID: 79955934157     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i16.2109     Document Type: Article

References (28)

1. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-117
2. Ala-aho R, Kähäri VM. Collagenases in cancer. Biochimie 2005; 87: 273-286
3. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121-125
4. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-2252
5. Nagase H, Barrett AJ, Woessner JF.Nomenclature and glossary of the matrix metalloproteinases. Matrix Suppl 1992; 1: 421-424
6. Saffarian S, Collier IE, Marmer BL, Elson EL, Goldberg G. Interstitial collagenase is a Brownian ratchet driven by prote-olysis of collagen. Science 2004; 306: 108-111
7. Boire A, Covic L, Agarwal A, Jacques S, Sherif S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120: 303-313
8. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621-1630
9. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 1996; 69: 9-16
10. Mori M, Mimori K, Sadanaga N, Inoue H, Tanaka Y, Mafune K, Ueo H, Barnard GF. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer 2000; 88: 575-578
11. Gress TM, Müller-Pillasch F, Lerch MM, Friess H, Büchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-413
12. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283
13. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Wax-man J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 1994; 70: 506-512
14. Oberg A, Höyhtyä M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000; 20: 1085-1091
15. Sobin LH, Wittekand CH, editors. TNM Classifcation of Malignant Tumors. 6th ed. New York: Wiley-Liss, 2002
16. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494
17. Sunami E, Tsuno N, Osada T, Saito S, Kitayama J, Tomo-zawa S, Tsuruo T, Shibata Y, Muto T, Nagawa H. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000; 5: 108-114
18. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kössi J, Hirsimäki P, Rahkonen O, Laato M. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121: 714-723
19. Shiozawa J, Ito M, Nakayama T, Nakashima M, Kohno S, Sekine I. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol 2000; 13: 925-933
20. Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003; 39: 1948-1956
21. Ylisirniö S, Höyhtyä M, Mäkitaro R, Pääakkö P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T, Jukkola A. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001; 7: 1633-1637
22. Muzzillo DA, Imoto M, Fukuda Y, Koyama Y, Saga S, Nagai Y, Hayakawa T. Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases. J Gastroenterol Hepatol 1993; 8: 437-441
23. Wang CS, Wu TL, Tsao KC, Sun CF. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Ann Clin Lab Sci 2006; 36: 23-30
24. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997; 36: 643-650
25. Papazoglou D, Papatheodorou K, Papanas N, Papadopoulos T, Gioka T, Kabouromiti G, Kotsiou S, Maltezos E. Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 levels in severely obese patients: what is the effect of weight loss? Exp Clin Endocrinol Diabetes 2010; 118: 730-734
26. Kardeşler L, Biyikoǧlu B, Cetinkalp S, Pitkala M, Sorsa T, Buduneli N. Crevicular fuid matrix metalloproteinase-8, -13, and TIMP-1 levels in type 2 diabetics. Oral Dis 2010; 16: 476-81
27. Karapanagiotidis GT, Antonitsis P, Charokopos N, Foroulis CN, Anastasiadis K, Rouska E, Argiriadou H, Rammos K, Pa-pakonstantinou C. Serum levels of matrix metalloproteinases -1,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia. J Cardiothorac Surg 2009; 4: 59
28. Sutnar A, Pesta M, Liska V, Treska V, Skalicky T, Kormunda S, Topolcan O, Cerny R, Holubec L. Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases. Tumour Biol 2007; 28: 247-252